PeptiDream Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
763
- Stock Symbol
-
4587
- Investments
-
11
- Share Price
-
$6.82
- (As of Monday Closing)
PeptiDream General Information
Description
PeptiDream Inc is engaged in the drug discovery and development business. The group utilizes PDPS, its proprietary drug discovery and development platform system, for drug discovery and development, and it conducts radiopharmaceutical business through a wholly owned subsidiary and is involved in the research, development, and manufacturing of pharmaceuticals, etc. Its reportable segments are Drug discovery and development business and Radiopharmaceutical business.
Contact Information
Website
www.peptidream.comCorporate Office
- 3-25-23 Tonomachi
- Kawasaki-ku
- Kawasaki, Kanagawa 210-0821
- Japan
Corporate Office
- 3-25-23 Tonomachi
- Kawasaki-ku
- Kawasaki, Kanagawa 210-0821
- Japan
PeptiDream Stock Performance
As of 16-Nov-2026, PeptiDream’s stock price is $6.82. Its current market cap is $876M with 129M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.82 | $6.66 | $5.63 - $11.47 | $876M | 129M | 801K | -$0.14 |
PeptiDream Financials Summary
As of 30-Sep-2026, PeptiDream has a trailing 12-month revenue of $130M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 859,125 | 1,289,379 | 1,979,919 | 1,401,863 |
| Revenue | 130,154 | 123,749 | 308,201 | 204,342 |
| EBITDA | (11,549) | (19,563) | 154,409 | 62,975 |
| Net Income | (18,391) | (25,050) | 99,142 | 21,606 |
| Total Assets | 451,995 | 492,455 | 590,777 | 492,548 |
| Total Debt | 95,519 | 108,942 | 125,036 | 157,560 |
PeptiDream Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PeptiDream Comparisons
Industry
Financing
Details
PeptiDream Competitors (43)
One of PeptiDream’s 43 competitors is AnGes, a Formerly VC-backed company based in Osaka, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AnGes | Formerly VC-backed | Osaka, Japan | ||||
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| Praxis (Drug Discovery) | Formerly VC-backed | Boston, MA | ||||
| Axsome Therapeutics | Formerly VC-backed | New York, NY | ||||
| Alivexis | Venture Capital-Backed | Cambridge, MA |
PeptiDream Patents
PeptiDream Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026211868-A1 | Agent for improving characteristics of peptide, and α-glucosidase | Pending | 31-Mar-2025 | ||
| WO-2026205491-A1 | Peptide, peptide complex, pharmaceutical composition, composition for cell culture, and composition for medical, diagnostic, or research use | Pending | 28-Mar-2025 | ||
| WO-2026127086-A1 | Drug | Pending | 11-Dec-2024 | ||
| WO-2026128539-A1 | Glypican-3 targeting compositions and uses thereof | Pending | 11-Dec-2024 | ||
| WO-2026121297-A1 | Conjugate comprising peptide and payload | Pending | 04-Dec-2024 |
PeptiDream Signals
PeptiDream Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
PeptiDream Investments & Acquisitions (11)
PeptiDream’s most recent deal was a Early Stage VC with LinkMed for . The deal was made on 09-Apr-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| LinkMed | 09-Apr-2025 | Early Stage VC | Drug Discovery | ||
| LinkMed | 22-Dec-2023 | Early Stage VC | Drug Discovery | ||
| PDR Pharma Co. | 28-Mar-2022 | Merger/Acquisition | Drug Discovery | ||
| Peptiaid | 01-Oct-2020 | Joint Venture | Drug Discovery | ||
| PeptiGrowth | 01-Apr-2020 | Joint Venture | Other Pharmaceuticals and Biotechnology |
PeptiDream ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
22.72 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
PeptiDream Exits (1)
PeptiDream’s most recent exit was on 13-Nov-2018 from Kleo Pharmaceuticals. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Kleo Pharmaceuticals | 13-Nov-2018 | Completed |
|
PeptiDream Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Peptiaid | Kawasaki City, Japan | 2020 | |
| Pdradiopharma | Tokyo, Japan |
PeptiDream FAQs
-
When was PeptiDream founded?
PeptiDream was founded in 2006.
-
Where is PeptiDream headquartered?
PeptiDream is headquartered in Kawasaki, Japan.
-
What is the size of PeptiDream?
PeptiDream has 763 total employees.
-
What industry is PeptiDream in?
PeptiDream’s primary industry is Drug Discovery.
-
Is PeptiDream a private or public company?
PeptiDream is a Public company.
-
What is PeptiDream’s stock symbol?
The ticker symbol for PeptiDream is 4587.
-
What is the current stock price of PeptiDream?
As of 16-Nov-2026 the stock price of PeptiDream is $6.82.
-
What is the current market cap of PeptiDream?
The current market capitalization of PeptiDream is $876M.
-
What is PeptiDream’s current revenue?
The trailing twelve month revenue for PeptiDream is $130M.
-
Who are PeptiDream’s competitors?
AnGes, Protagonist Therapeutics, Praxis (Drug Discovery), Axsome Therapeutics, and Alivexis are some of the 43 competitors of PeptiDream.
-
What is PeptiDream’s annual earnings per share (EPS)?
PeptiDream’s EPS for 12 months was -$0.14.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process